PROTOPIC Drug Patent Profile

Which patents cover Protopic, and what generic alternatives are available?

Protopic is a drug marketed by Leo Pharma As and is included in one NDA.

The generic ingredient in PROTOPIC is tacrolimus. There are twenty drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the tacrolimus profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Protopic

A generic version of PROTOPIC was approved as tacrolimus by SANDOZ on August 10^th, 2009.

Summary for PROTOPIC

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for PROTOPIC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PROTOPIC	Ointment	tacrolimus	0.03%	050777	1	2010-11-22
PROTOPIC	Ointment	tacrolimus	0.10%	050777	1	2010-09-09

US Patents and Regulatory Information for PROTOPIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	PROTOPIC	tacrolimus	OINTMENT;TOPICAL	050777-001	Dec 8, 2000	AB	RX	Yes	Yes
Leo Pharma As	PROTOPIC	tacrolimus	OINTMENT;TOPICAL	050777-002	Dec 8, 2000	AB	RX	Yes	Yes

International Patents for PROTOPIC

See the table below for patents covering PROTOPIC around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	503236	Ny användning av 23,25-dimetoxi-13,19,21,27-tetrametyl-11,28- dioxa-4-azatricyclo]8(] 22.3.1.0]64]6.]69]8)]-]4oktakos-18-en -2,3,10,16-tetraon-derivat för framställning av läkemedel för topisk behandling av psoriasis och atopisk dermatit
Hungary	T59002
Netherlands	8802734

Investment Scenario and Fundamentals Analysis for PROTOPIC (Tacrocolimus)

Last updated: February 20, 2026

What is PROTOPIC and its current market position?

PROTOPIC is a topical immunosuppressant containing tacrolimus, primarily prescribed for atopic dermatitis. Marketed by Astellas Pharma, it gained approval in multiple jurisdictions, including the U.S. (2000) and Europe (2002). Its patent expired in the U.S. in 2018, leading to increased generic competition. Nonetheless, it retains segments of branded market share, especially in formulations combined with other therapies or in specific patient populations.

How does the patent landscape influence future revenue?

Astellas' main patent for PROTOPIC expired in 2018, opening market share to generics. However, patent extensions and formulation patents temporarily delayed generic penetration, especially in Europe. Patent expiry has driven revenue decline, with U.S. sales decreasing from approximately $500 million in 2017 to below $250 million recently, according to IQVIA data. New formulations or formulations with bioavailability claims, such as compounded topical versions, may delay generic substitution further.

What are the key market dynamics?

The global topical dermatology market was valued at roughly $8.2 billion in 2022, with a compound annual growth rate (CAGR) of about 4.2%. PROTOPIC holds an estimated 3-4% share of the atopic dermatitis market globally. Growth drivers include:

• Rising prevalence of atopic dermatitis
• Increasing recognition of topical immunomodulators
• Shift from systemic immunosuppressants to topical options

However, the entry of generics has put downward pressure on pricing and margins.

What are the competitive threats and opportunities?

Threats:

• Price erosion from generics in major markets
• Competition from other topical treatments, including corticosteroids, calcineurin inhibitors, and emerging biologics
• Changes in prescribing guidelines favoring biologicals for severe cases

Opportunities:

• Label expansions in pediatric populations and other dermatologic indications
• Development of combination formulations
• Patent filings for new delivery systems or formulations, extending exclusivity

What are the R&D and regulatory prospects?

Research focuses on new delivery mechanisms (e.g., nanotechnology-based formulations), with preclinical data indicating improved skin penetration and reduced systemic absorption. Regulatory efforts are underway for:

• Importing new formulations in markets with high unmet needs
• Pursuing filings for pediatric indications and other dermatologic conditions

These efforts could preserve or enhance sales paradigms if approved.

Financial fundamentals and valuation considerations

The revenue dependence on aging patents and generic competition indicates declining profitability. Core financials:

Metric	2021	2022	Trend	Notes
Revenue	~$300 million	~$200 million	Declining	Due to patent loss and generic entries
R&D Spend	~$25 million	~$30 million	Slight increase	Focused on formulation innovation
Operating Margin	~35%	~25%	Declining	Price erosion impact

Given the patent cliffs, valuation models should incorporate declining revenue streams and potential upside from new formulations or indications. Discounted cash flow (DCF) analysis must assume revenue erosion over the next 3-5 years unless new breakthroughs or regulatory approvals are achieved.

Investment outlook

The outlook for PROTOPIC relies heavily on innovation, extension strategies, and market penetration in emerging regions. Without patent protection, branded revenues are under pressure. Key catalysts include:

• FDA or EMA approval for new formulations or indications
• Corporate strategies such as licensing or alliance formations
• Entry into adjacent dermatology segments

The typical risk profile involves patent expiration impact, competitive pressure, and R&D success probability.

Key considerations for investors

• Patent expiration timing and patent extensions
• Pipeline development progress
• Competitive landscape shifts, especially biologics and novel small molecules
• Regional market growth rates and formulary coverage

Key Takeaways

• PROTOPIC faces revenue decline due to patent expiry and generic competition.
• Market size is growing modestly; however, branded share diminishes.
• R&D investments focus on formulation innovation and expanding indications.
• Regulatory approvals for new formulations or uses could provide revenue inflections.
• Financials show declining margins; valuation models should reflect this trend unless new value drivers materialize.

FAQs

1. What is the primary indication for PROTOPIC?
Atopic dermatitis, particularly in pediatric and adult populations.

2. How does patent expiry affect PROTOPIC’s revenue?
It opened the market to generics, reducing prices and sales revenues of branded formulations.

3. Are there opportunities for PROTOPIC in new indications?
Yes, research into other dermatologic conditions or combination therapies could expand the market.

4. How significant is generics’ market penetration currently?
In the U.S., generics account for over 80% of the topical tacrolimus market, significantly impacting branded sales.

5. Will PROTOPIC’s R&D efforts restore profitability?
Potentially if new formulations or indications gain regulatory approval; otherwise, revenue decline may continue.

---

References
[1] IQVIA. (2023). Topical dermatology sales data.
[2] Astellas Pharma Inc. (2022). Annual report.
[3] European Medicines Agency. (2002). Approval documentation for PROTOPIC.
[4] U.S. Food and Drug Administration. (2018). Patent expiration notices.